Document is current
Any future updates will be listed below
-
Authors
Mori, Sho
Shabana, Kosuke
Matsui, Toshihiro
Nozawa, Tomo
Sugita, Yuko
Tomiita, Minako
Nakagishi, Yasuo
Yamasaki, Yuichi
Umebayashi, Hiroaki
Yashiro, Masato
Iwata, Naomi
Yasumura, Junko
Wakiguchi, Hiroyuki
Yamamoto, Takeshi
Takezaki, Shunichiro
Okura, Yuka
Yokoyama, Tadafumi
Shimizu, Masaki
Hirayama, Masahiro
Tohma, Shigeto
Okamoto, Nami
Mori, Masaaki
-
Funding
Funding for this research was provided by:
the Japan Agency for Medical Research and Development (25ek0410112h0003)
- License Information
-
More Information
Article History
Received: 19 June 2025
Accepted: 17 October 2025
First Online: 24 November 2025
Declarations
:
: The CoNinJa study protocol was reviewed and approved by the Ethics Review Board of Institute of Science Tokyo (Tokyo Medical and Dental University), the primary study center (approval No: M2016-256). Additional approvals were obtained from the ethics committees of the 15 other participating medical institutions. Guardians and patients were informed through an opt-out procedure. The NinJa study protocol was reviewed and approved by the Ethics Committee of the NHO Sagamihara National Hospital (approval No: 2014031816) and the ethics committees of all participating institutions. In accordance with the decisions of the respective ethics committees, the study was conducted either with written informed consent obtained from patients or through an opt-out approach. All authors approved the final version of the manuscript for publication and agree to take responsibility for any part of the work.
: Not applicable.
: S.M. and K.S. have no conflict of interest to disclose. T.M. has received speaking fees and/or honoraria from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd., Ayumi Pharmaceutical, Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Taisho Pharmaceutical Co. Ltd., and UCB Japan Co. Ltd. and has received research grant from Asahi KASEI Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Mitsubishi-Tanabe Pharma Co. N.I. received a lecture fee from Mitsubishi Tanabe Pharma Corporation, Glaxo Smith Kline plc, AbbVie GK, Ono Pharmaceutical co. M.S. has received speaking fees from Novartis Phama Co., Ltd. and has received research grant from MBL Co. Ltd. N.O. received speaker fee and/or honoraria from AbbVie, Bristol-Myers Squib, Eli Lilly, GlaxoSmithKline, Mitsubishi Tanabe, Ono, Ayumi, Novartis and UCB. M.M has received unrestricted research grants for the previous Department of Lifetime Clinical Immunology from AbbVie GK, Ayumi Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Japan Blood Products Organization, Nippon Kayaku Co., Ltd., UCB Japan Co. Ltd., Asahikasei Pharmaceutical Corporation.
